S100β is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase

Anticancer Research

Volumn 21, Issue 2 B, 2001, Pages 1311-1316

  Krahn G ^a   Kaskel, P ^a   Sander, S ^a   Pereira Y Waizenhofer J ^a   Wortmann, S ^a   Leiter, U ^a   Peter, R U ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Albumin; Lactate dehydrogenase; Melanoma; Melanoma inhibiting activity; Melanoma inhibitory activity; Metastasis; S100; Tumor marker

Indexed keywords

ALBUMIN; LACTATE DEHYDROGENASE; MELANOMA INHIBITING ACTIVITY; S100BETA PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ALBUMINS; BRAIN NEOPLASMS; CALCIUM-BINDING PROTEINS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; NEOPLASM PROTEINS; NEOPLASM STAGING; NERVE GROWTH FACTORS; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035015137     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. The emerging epidemic of melanoma and squamous cell carcinoma
2. Elevation of a serum component in neoplastic disease
3. Usefulness of an elevated serum lactate dehydrogenase value as a marker of hepatic metastases in malignant melanoma
4. LDH and melanoma
5. Evaluation of staging workup in malignant melanoma
6. LDH in the follow-up of stage I malignant melanoma
7. Regression analysis of prognostic factors in metastatic malignant melanoma
8. Prognostic factors in patients with metastatic malignant melanoma
9. Treatment of uveal melanoma metastatic to the liver
10. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma
11. Prognostic factors for survival of patients treated systemically for disseminated melanoma
12. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma
13. S100 protein is present in cultured human malignant melanomas
14. Detection of S-100 protein as an aid to the identification of melanocytic tumours
15. S-100 protein as a marker for melanocytic and other tumours
16. S-100 protein remains a practical marker for melanocytic and other tumours
17. The S100 family of EF-hand calcium-binding proteins: Functions and pathology
18. Ions binding to S100 proteins
19. Clinical significance of serum S100 in metastatic malignant melanoma
20. Serum S100 - A marker for disease monitoring in metastatic melanoma
21. Evaluation of new putative markers for melanoma
22. Prognostic value of serum analyses of S-100b protein in malignant melanoma
23. Serum S-100 protein: A potentially useful prognostic marker in cutaneous melanoma
24. Elevated serum levels of S100 and survival in metastatic malignant melanoma
25. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumours and ischemic disorders of the central nervous system
26. S-100 protein in peripheral blood: A marker for melanoma metastases. A prospective 2-center study of 570 patients with melanoma
27. The luminescence immunoassay S-100: A sensitive test to measure circulating S-100B: Its prognostic value in malignant melanoma
28. Sangtec S100 LIA a new sensitive monoclonal assay for measuring protein S-100 in patients with malignant melanoma
29. Cutaneous malignant melanoma. Publicity, screening clinics and survival - The Edinburgh experiences 1982-90
30. Prognostic parameters in uveal melanoma: A review
31. MIA (melanoma inhibitory activity): A potential serum marker for rheumatoid arthritis